Clinical Trials Browser

Phase 2 × Interventional × Targeted Therapy × Clear all

NCT07032727 2025-12-15

Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations

Phase 2 Recruiting

Targeted Therapy